Revium Rx. Annual Report - How They Did This Year

I’ve put together this guide to help you understand Revium Rx.’s performance this past year. My goal is to turn complex financial filings into plain English so you can decide if this company belongs in your portfolio.

1. The Big Picture

Revium Rx. acts like the "engineers" of the medicine world. They build tiny, fat-based particles called liposomes. Think of these as microscopic envelopes that carry medicine directly to tumors or infections. This helps drugs work better while causing fewer side effects. They are currently researching ways to treat antibiotic-resistant bacteria and cancer. Their technology improves how potent drugs move through the body, preventing them from breaking down too quickly or becoming toxic.

2. A Major Pivot

If you follow this company, you will notice a big change. In July 2024, Revium Rx. moved away from mental health software to acquire a private biotech firm called LipoVation. To pay for this, Revium issued 15 million new shares to LipoVation’s owners. This means your ownership percentage in the company was reduced. They have sold off their old software business and are now 100% focused on nanoparticle medicine. It is a total reboot, shifting from software services to the expensive world of drug development.

3. The Science (The "Why")

Their technology is inspired by Professor Barenholz, who helped create Doxil®, a successful drug that generated billions in sales. Their lead project, Nano-Mupirocin, shows real promise. Standard mupirocin is a strong antibiotic, but it disappears from the bloodstream in under 30 minutes. Revium’s "envelope" keeps the drug active much longer. In animal studies, it stayed in the bloodstream 50 times longer than the standard version. This is critical for treating "superbugs" like MRSA, where the drug must stay in the blood to be effective.

4. Financial Health

This is the most important section to watch. Revium Rx. currently has zero sales revenue. They lost $4.2 million this year, mostly due to $2.8 million in research costs and $1.4 million in administrative expenses. They ended the year with $1.8 million in cash. At their current spending rate, they have enough money to last about 6 to 9 months. They must raise more money or partner with a large pharmaceutical company within the next six months to avoid running out of cash.

5. The "Watch Out" List

• The "Pre-Clinical" Gap: Their science works in animals, but they haven't tested it in humans yet. Many drugs fail when moving to human trials because they behave differently in our bodies.
• Cash Flow: Because they have no revenue and high costs, they will likely issue more shares to raise money. This reduces the value of your existing shares.
• Regulatory Hurdles: They must get FDA approval to start human trials. Any delays in this process will increase costs and push back their timeline.
• Legal Uncertainty: They are in a dispute over the rights to one of their drugs, Nano-Candesartan. Losing this case would remove a major project from their pipeline and hurt the company's value.
• Long Road Ahead: They are years away from selling a product. They are currently preparing for safety studies that won't finish until late 2026. Only then can they ask the FDA for permission to start human trials.

Final Thought for Your Portfolio: Revium Rx. is essentially a high-stakes research project. Because they have no revenue and a very short cash runway, they are in a "make or break" period. If you are considering an investment, keep a close eye on their next funding announcement—it will be the biggest indicator of whether they can survive long enough to get their technology into human trials.